Crohn's disease(CD),a type of inflammatory bowel disease(IBD), is a chronic intestinal recurrent inflammatory disease involving the entire digestive tract. And Ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, is a newly targeted drug approved for the treatment of Crohn's disease in recent years.Based on the high-throughput imaging characteristic analysis technique, this study quantitatively analyzed the transmural inflammation of Crohn's disease, and discussed its prognostic value in the treatment of Ustekinumab, and further analyzed the increment of its relative clinical index.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
endoscopic remission rate at 12 months
Timeframe: 12 months after first intervention administration
normalization rate of serum biomarker at 12 months
Timeframe: 12 months after first intervention administration
clinical remission rate at 12 months
Timeframe: 12 months after first intervention administration
clinical response rate at 12 months
Timeframe: 12 months after first intervention administration
endoscopic response rate at 12 months
Timeframe: 12 months after first intervention administration
life quality changes at 12 months
Timeframe: 12 months after first intervention administration
endoscopic remission rate after induction therapy
Timeframe: 16 or 20 weeks after first intervention administration
normalization rate of serum biomarker after induction therapy
Timeframe: 16 or 20 weeks after first intervention administration
clinical remission rate after induction therapy
Timeframe: 16 or 20 weeks after first intervention administration
clinical response rate after induction therapy
Timeframe: 16 or 20 weeks after first intervention administration
endoscopic response rate after induction therapy
Timeframe: 16 or 20 weeks after first intervention administration
life quality changes after induction therapy
Timeframe: 16 or 20 weeks after first intervention administration